Almost every explainer on BPC-157 opens the same way: it's a synthetic 15-amino-acid fragment of a larger "body protection compound" protein found in human gastric juice. That sentence is repeated in product pages, clinic blogs and peer-reviewed reviews alike. In 2026 a pair of investigative reports and the president of the American Peptide Society asked a question that most BPC-157 research quietly skips: where is that parent protein? If you want the short answer on what is BPC-157 and whether it's legal here, our BPC-157 profile covers the basics — this piece is about the origin story itself, and why the gap in it matters when you read the literature.

What Is BPC-157 Supposed to Be?

BPC-157 is a laboratory-synthesised pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It was characterised from the early 1990s by Predrag Sikirić and colleagues at the University of Zagreb, and the standard account is that the 15 residues represent the active portion of a much larger protein present in mammalian gastric juice.

That framing does real work. It is why BPC-157 is routinely described as "naturally occurring", "body-derived" or "a fragment of something your stomach already makes" — language that implies a built-in safety margin. The compound is not approved as a medicine anywhere in the world, so the origin story is doing a lot of the persuading.

The Parent Protein Has Never Been Published

A May 2026 investigation by Undark, co-published with STAT, spent months on the compound's history, including extensive access to Sikirić's lab in Zagreb. Its central scientific finding was not about efficacy — it was about provenance.

No published sequence

Anna Mapp, professor of chemistry at the University of Michigan and president of the American Peptide Society, told the reporters that the sequence of BPC-157's supposed parent protein has never been published. Her point was methodological rather than rhetorical: without that sequence, the founding isolation work cannot be reproduced by anyone else. For a compound with three decades of downstream literature, that is an unusual foundation.

No genomic address

The investigation also reported that genetic material coding for BPC-157 has not been located in the human genome, nor in the gut microbiome. Peptides that genuinely derive from a human protein have a gene you can point to. This one, so far, does not.

No identified receptor

Separately, researchers quoted in the coverage noted that no receptor for BPC-157 has been identified — the molecular handle through which most peptide therapeutics are understood to act. Sikirić has not made receptor identification a focus of his work. That absence doesn't prove a compound is inert, but it does mean mechanistic claims rest on downstream observations (angiogenesis, nitric-oxide signalling) rather than a mapped target.

Sikirić's Answer

He rejects the framing. In a June 2026 interview with STAT, Sikirić disputed the suggestion that BPC-157 is not a naturally occurring substance, and pointed to decades of animal and cell work reporting broad healing effects with few observed adverse effects. His proposed mechanism centres on vascular repair and regulation of the nitric-oxide system rather than a single receptor.

It is worth reporting that fairly. "The parent protein hasn't been published" and "the compound does nothing" are different claims, and only the first is currently supported. But the burden of demonstrating the first is on the originating lab, and after thirty years it remains outstanding.

A Dispute That Reached the Journals

This is not purely a journalism story. In 2025, Pharmaceuticals published a literature and patent review by Józwiak and colleagues that raised theoretical concerns about BPC-157 — among them whether sustained pro-angiogenic and nitric-oxide effects could cut both ways. Sikirić and co-authors published a formal Comment rejecting that reading; the original authors published a Reply. Both appeared in October 2025.

Read together, the exchange is a useful reality check for anyone doing their own BPC-157 research: the specialists are still arguing about mechanism and risk direction, not fine-tuning a dose. You can see the same pattern across the wider peptide space — heavy preclinical volume, thin translational output.

What the Evidence Base Actually Is

A 2025 review in HSS Journal found that 35 of 36 studies it assessed were preclinical. No randomised controlled trial of BPC-157 in humans has been published for any indication. The animal literature is large — well over a hundred studies reporting faster healing of tendon, muscle and gut tissue in rodents — but it is heavily concentrated in one research group, which is precisely why the unreproducible starting point matters. Independent replication is the mechanism by which a single lab's findings become knowledge, and it has largely not happened here.

Is BPC-157 Legal in Australia?

Yes, this part is settled. Since 1 June 2024, BPC-157 has been listed in Schedule 4 of the Poisons Standard and in Appendix D, the most restrictive category for prescription substances. In practical terms, possessing BPC-157 in Australia without lawful authority is illegal, and it is not an approved medicine here or in any other jurisdiction.

Two further points Australian readers should hold onto:

  • Sport. BPC-157 has been on the WADA Prohibited List since 2022, in and out of competition. Anyone tested under a WADA-compliant code — which includes most Australian sporting bodies — is exposed.
  • The US situation is not a green light. BPC-157 left the FDA's Category 2 compounding bulks list in April 2026 after the nomination was withdrawn, and a July 2026 PCAC vote followed. That vote is advisory only, and BPC-157 is still not lawfully compoundable in the United States. It changes nothing about Australian scheduling.

How to Read BPC-157 Claims From Here

Three questions cut through most of the marketing:

  1. Is the claim from a human study? Almost certainly not — assume rodent unless shown otherwise.
  2. Is it from an independent lab? Concentration of evidence in one group is a replication problem, not a conspiracy.
  3. Does it lean on "natural" or "body-derived"? That framing is exactly the part now under scrutiny.

Want these breakdowns as they land? Join the free updates list — no product pitches, just what the evidence says.

FAQ

What is BPC-157 derived from?

It is described as a fragment of a larger "body protection compound" protein said to occur in human gastric juice. As of 2026, that parent protein's sequence has never been published and no corresponding gene has been located in the human genome.

Is BPC-157 legal in Australia?

No, not for general possession. Since 1 June 2024 it has been Schedule 4 plus Appendix D under the Poisons Standard, so possessing it without lawful authority is illegal, and it is not an approved medicine anywhere in the world.

Are there any human trials of BPC-157?

No randomised controlled trial in humans has been published for any indication. A 2025 HSS Journal review found 35 of 36 studies it assessed were preclinical.

Does BPC-157 have a known receptor?

Not one that has been identified and published. Researchers have flagged this as a gap, since most peptide therapeutics are understood through a defined receptor target.

Sources

This article is information only, not medical advice. BPC-157 is not an approved medicine in Australia or any other country and is Schedule 4/Appendix D here; retatrutide.net.au is independent and does not sell or supply any compound.